LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Creating an inclusive climate within pharmacy practice.

    Adams, Kathleen K / Brown, Britny R

    Currents in pharmacy teaching & learning

    2023  Volume 15, Issue 1, Page(s) 52–56

    Abstract: Objective: Identify the impact of a brief, educational intervention on student pharmacist understanding of unconscious bias and its systemic effects; cultural humility; and commitment to change.: Methods: A pre-intervention survey, with questions ... ...

    Abstract Objective: Identify the impact of a brief, educational intervention on student pharmacist understanding of unconscious bias and its systemic effects; cultural humility; and commitment to change.
    Methods: A pre-intervention survey, with questions utilizing a five-point Likert scale was embedded into the beginning of a series of online, interactive, educational modules addressing cultural humility, unconscious bias, and inclusive pharmacy practices. Third-year professional pharmacy students completed the course as part of their curriculum. At the conclusion of the modules, participants completed the post-intervention survey with the same set of questions, which was linked to the pre-intervention survey by a participant-generated code. Changes in means for the pre- and post-intervention cohorts were calculated and analyzed utilizing a Wilcoxon signed-rank test. Responses were also grouped dichotomously and evaluated using the McNemar test.
    Results: Sixty-nine students completed both the pre- and post-intervention surveys. The greatest change on Likert scale questions was noted in understanding of cultural humility (+1.4). Much or complete confidence in being able to describe unconscious bias and cultural competence improved from 58% to 88% and 14% to 71%, respectively (P < .05). Although a trend toward positive change was noted, a significant impact was not observed for questions assessing understanding of their systemic effects and commitment to change.
    Conclusion: Interactive educational modules positively impact student understanding of unconscious bias and cultural humility. Further investigation is necessary to determine if continuous exposure to this and similar topics deepens student understanding of systemic impact and commitment to change.
    MeSH term(s) Humans ; Pharmacy ; Pharmaceutical Services ; Curriculum ; Pharmacists ; Students, Pharmacy
    Language English
    Publishing date 2023-03-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2515217-8
    ISSN 1877-1300 ; 1877-1297
    ISSN (online) 1877-1300
    ISSN 1877-1297
    DOI 10.1016/j.cptl.2023.02.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Association of guideline-concordant care with survival, health care utilization, and costs among older women with advanced epithelial ovarian cancer.

    Kamat, Shweta / Brown, Britny R / Hume, Anne / Vyas, Ami

    The American journal of managed care

    2023  Volume 29, Issue 10, Page(s) e292–e298

    Abstract: Objectives: To examine guideline-concordant care (GCC) for ovarian cancer, identify its predictors, and evaluate the associations between GCC and survival, health care expenditures, and utilization.: Study design: A retrospective cohort study using ... ...

    Abstract Objectives: To examine guideline-concordant care (GCC) for ovarian cancer, identify its predictors, and evaluate the associations between GCC and survival, health care expenditures, and utilization.
    Study design: A retrospective cohort study using Surveillance, Epidemiology, and End Results-Medicare data.
    Methods: Women aged 66 to 90 years who received a diagnosis of stage II or higher epithelial ovarian cancer during 2011-2015 were included (N = 3237). The National Comprehensive Cancer Network clinical practice guidelines were used to identify GCC. Logistic regression was conducted to identify predictors of GCC, a Cox proportional hazards model was used to examine mortality, and generalized linear models were used to examine mean monthly Medicare expenditures and health care utilization.
    Results: Approximately 57% of women received GCC and 11.6% of women did not receive any cancer-specific treatment. Women who were relatively older (adjusted odds ratio [AOR], 0.272; 95% CI, 0.210-0.351), had Census tract income of $50,000 or less (AOR, 0.709; 95% CI, 0.551-0.913), had a psychiatric condition (AOR, 0.655; 95% CI, 0.464-0.923), and had adenocarcinoma histology (AOR, 0.564; 95% CI, 0.441-0.721) were significantly less likely to receive GCC. Race/ethnicity was not found to be a significant predictor of GCC. Women who received surgery only or chemotherapy only had a significant higher hazard of all-cause mortality and ovarian cancer-specific mortality compared with those who received GCC (surgery only: adjusted HR [AHR], 2.307; chemotherapy only: AHR, 1.802). Receiving chemotherapy only was associated with 45% (P < .0001) higher mean monthly expenditures compared with those who received GCC.
    Conclusions: Non-GCC was associated with worsened survival, higher health care utilization, and increased expenditures. It is important to highlight that women who received GCC were associated with better survival likely due to favorable prognostic clinical factors.
    MeSH term(s) Aged ; Humans ; Female ; United States ; Carcinoma, Ovarian Epithelial/therapy ; Medicare ; Retrospective Studies ; Patient Acceptance of Health Care ; Ovarian Neoplasms/therapy
    Language English
    Publishing date 2023-10-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2035781-3
    ISSN 1936-2692 ; 1088-0224 ; 1096-1860
    ISSN (online) 1936-2692
    ISSN 1088-0224 ; 1096-1860
    DOI 10.37765/ajmc.2023.89443
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Comparative cost savings of biosimilar and dose rounding utilization in oncology care.

    Abdelmeseh, Verona / Brown, Britny R / Huynh, Justin P / Zullo, Andrew R

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

    2022  Volume 29, Issue 6, Page(s) 1437–1442

    Abstract: Introduction: The exponential rise in cancer costs has led many centers to utilize dose rounding to the nearest vial size when the difference in dose is ≤10% to decrease costs. The recent approval of several biosimilar products has presented another ... ...

    Abstract Introduction: The exponential rise in cancer costs has led many centers to utilize dose rounding to the nearest vial size when the difference in dose is ≤10% to decrease costs. The recent approval of several biosimilar products has presented another opportunity to mitigate the rising costs of oncology care. Scarce information exists about the expected cost savings of combining dose rounding strategies (DRS) with biosimilar use (BU). We therefore assessed the cost savings of combining DRS and BU.
    Methods: Electronic health record data for two health systems in Rhode Island were used to identify patients who received ≥1 of trastuzumab, trastuzumab-anns, bevacizumab, or bevacizumab-awwb from October 1, 2015 to September 1, 2020. Costs were estimated using Medicare drug pricing. Multivariable generalized estimating equations adjusting for age, gender, presence of metastases, dosing weight, and dose administered were used to compare costs per dose between the four exposure groups: DRS + BU, DRS only, BU only, and neither DRS or BU.
    Results: A total of 1156 patients were administered 15,145 doses of drug. After covariate adjustment, average savings per dose was greatest in the DRS + BU group (vs. the neither DRS nor BU group); $331 for trastuzumab and $497 for bevacizumab.
    Conclusions: Combining dose rounding with biosimilar substitution for trastuzumab and bevacizumab resulted in significant cost savings per dose and should be implemented by healthcare systems.
    MeSH term(s) United States ; Humans ; Aged ; Bevacizumab ; Antineoplastic Agents ; Biosimilar Pharmaceuticals/therapeutic use ; Cost Savings ; Drug Costs ; Medicare ; Trastuzumab/therapeutic use
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; Antineoplastic Agents ; Biosimilar Pharmaceuticals ; Trastuzumab (P188ANX8CK)
    Language English
    Publishing date 2022-10-19
    Publishing country England
    Document type Journal Article
    ZDB-ID 1330764-2
    ISSN 1477-092X ; 1078-1552
    ISSN (online) 1477-092X
    ISSN 1078-1552
    DOI 10.1177/10781552221134257
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Adverse Events Induced by Nivolumab Plus Ipilimumab

    Kamat, Shweta / Patel, Jay / Brown, Britny R / Vyas, Ami

    Cancer investigation

    2022  Volume 40, Issue 9, Page(s) 777–788

    Abstract: A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI) compared to NIVO monotherapy among cancer patients. ... ...

    Abstract A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI) compared to NIVO monotherapy among cancer patients. We searched several databases to identify relevant RCTs. Meta-analysis was performed using random-effects model. In fourteen RCTs included in the study, we found that compared to NIVO monotherapy, combination NIVO + IPI increased the risk of any grade (Risk Ratio (RR) = 1.11), and grade 3 or 4 (RR = 1.95) TRAEs. Compared to NIVO, NIVO + IPI had higher risk for any grade colitis (RR = 4.52), pneumonitis (RR = 3.06), and diarrhea (RR = 1.68).
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Ipilimumab/adverse effects ; Neoplasms/drug therapy ; Neoplasms/etiology ; Nivolumab/adverse effects
    Chemical Substances Ipilimumab ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2022-08-14
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 604942-4
    ISSN 1532-4192 ; 0735-7907
    ISSN (online) 1532-4192
    ISSN 0735-7907
    DOI 10.1080/07357907.2022.2108827
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The implications of data aggregation on propagating racial and ethnic disparities within the health care landscape: Actionable recommendations and considerations for pharmacists.

    Camara, Emma / Safri, Ana / Ko, Caroline L / Abdul-Mutakabbir, Jacinda C / Bandali, Aiman / Brown, Britny R

    Journal of the American Pharmacists Association : JAPhA

    2023  Volume 64, Issue 1, Page(s) 34–38.e1

    Abstract: As the U.S. population becomes more racially and ethnically diverse, it is increasingly important to characterize health inequities for targeted intervention. As it stands, demographic data regarding race and ethnicity for patients and pharmacy trainees ... ...

    Abstract As the U.S. population becomes more racially and ethnically diverse, it is increasingly important to characterize health inequities for targeted intervention. As it stands, demographic data regarding race and ethnicity for patients and pharmacy trainees alike are aggregated into heterogenous population groups, resulting in findings that may inaccurately reflect the experiences of smaller subgroups. Disaggregation of patient outcomes data can serve to better inform public health interventions for the most vulnerable populations. In pharmacy, disaggregation can allow for better identification of racial and ethnic subgroups who have been traditionally excluded from funding support among other opportunities. In this commentary, we provide historical context and actionable recommendations to better describe our patient and pharmacy trainee populations, with the objectives of improving pharmacist representation and health equity.
    MeSH term(s) Humans ; Pharmacists ; Data Aggregation ; Ethnicity ; Pharmaceutical Services ; Delivery of Health Care
    Language English
    Publishing date 2023-10-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2118585-2
    ISSN 1544-3450 ; 1544-3191 ; 1086-5802
    ISSN (online) 1544-3450
    ISSN 1544-3191 ; 1086-5802
    DOI 10.1016/j.japh.2023.10.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: A call to action: A need for initiatives that increase equitable access to COVID-19 therapeutics.

    Abdul-Mutakabbir, Jacinda C / Hirsch, Elizabeth B / Ko, Caroline / Brown, Britny R / Bandali, Aiman / Mordino, Jason / Yoke, Leah H / Bell, Taison / Swartz, Talia H / Syed, Uzma / Hlatshwayo, Matifadza / Saunders, Ila M

    Lancet regional health. Americas

    2022  Volume 11, Page(s) 100263

    Language English
    Publishing date 2022-05-18
    Publishing country England
    Document type Journal Article
    ISSN 2667-193X
    ISSN (online) 2667-193X
    DOI 10.1016/j.lana.2022.100263
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Brighter horizons: The necessity of concentrated sponsorship targeted toward minoritized student pharmacists.

    Ko, Caroline L / Abdul-Mutakabbir, Jacinda C / Astle, Kevin N / Bandali, Aiman / Brown, Judah E / Childs-Kean, Lindsey M / Hirsch, Elizabeth B / Mordino, Jason / Saunders, Ila M / Brown, Britny R

    Journal of the American Pharmacists Association : JAPhA

    2022  Volume 62, Issue 3, Page(s) 701–705

    Abstract: Due to the effects of structural racism, disproportionately lower numbers of Black, Hispanic or LatinX, American Indian, and Alaska Native students pursue a career in pharmacy and successfully matriculate into the profession. Despite these disparities ... ...

    Abstract Due to the effects of structural racism, disproportionately lower numbers of Black, Hispanic or LatinX, American Indian, and Alaska Native students pursue a career in pharmacy and successfully matriculate into the profession. Despite these disparities being present for many years, little progress has been achieved in diversifying the pharmacy profession, resulting in a persistent lack of diversity within pharmacy leadership across employers and pharmacy organizations. Consistent with recent recommendations for improving diversity in pharmacy, the PharmGradWishlist (PGWL) initiative was created as a way for practicing pharmacists and organizations to provide direct financial sponsorship to racially and ethnically minoritized trainees to offset costs incurred during training and during the transition from student to practicing pharmacist. Many of these costs, such as residency and fellowship application fees, job interview travel costs, board exam and licensing fees, and moving expenses, are not typically subsidized by federal student funding. Offsetting these costs is an important way to reduce barriers to entering the profession and postgraduate training, the latter of which may be particularly important in trainees' pursuit of academic and leadership positions in pharmacy. The initial development and advertisement of the initiative occurred through social media and the grassroots efforts of the PGWL team, a group of 10 volunteer pharmacists from across the country, and resulted in generous donations from a small proportion of practicing pharmacists nationwide. It is now time for the profession as a whole to embrace the role of direct sponsorship in improving diversity in the profession. We call upon pharmacists and pharmacy organizations to advocate for and participate in financial sponsorship of racially and ethnically minoritized trainees and pharmacists as a way to increase diversity and promote health equity.
    MeSH term(s) Education, Pharmacy ; Health Promotion ; Humans ; Pharmacists ; Pharmacy ; Students, Pharmacy
    Language English
    Publishing date 2022-03-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2118585-2
    ISSN 1544-3450 ; 1544-3191 ; 1086-5802
    ISSN (online) 1544-3450
    ISSN 1544-3191 ; 1086-5802
    DOI 10.1016/j.japh.2022.03.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top